Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- doxorubicin
- Livtencity (maribavir)
Interactions between your drugs
DOXOrubicin maribavir
Applies to: doxorubicin, Livtencity (maribavir)
MONITOR: Coadministration with maribavir may increase the plasma concentrations of drugs that are substrates of the breast cancer resistance protein (BCRP) transporter. The proposed mechanism is decreased clearance due to maribavir-mediated inhibition of the BCRP transport protein. There are no clinical data regarding the use of maribavir with BCRP substrates.
MANAGEMENT: Caution is advised when maribavir is prescribed with drugs that are BCRP substrates, particularly those with a narrow therapeutic range. Clinical and laboratory monitoring as well as dosage adjustments may be appropriate for some drugs whenever maribavir is added to or withdrawn from therapy.
References (1)
- (2021) "Product Information. Livtencity (maribavir)." Takeda Pharmaceuticals America
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Carvykti
Carvykti (ciltacabtagene autoleucel) is used for the treatment of relapsed or refractory multiple ...
Abecma
Abecma is a CAR T cell therapy used to treat relapsed refractory multiple myeloma (RRMM); it is a ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Tecvayli
Tecvayli (teclistamab) is a treatment for relapsed or refractory multiple myeloma. Includes ...
Verzenio
Verzenio is used to treat early and advanced-stage hormone receptor-positive, HER2-negative breast ...
Trodelvy
Trodelvy (sacituzumab govitecan) is a targeted therapy used to treat breast cancer (triple-negative ...
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Talvey
Talvey is used to treat relapsed or refractory multiple myeloma. Includes Talvey side effects ...
Kisqali
Kisqali (ribociclib) is used to treat a certain type of advanced metastatic breast cancer. Includes ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.